



**MiSight® Spectacle Lenses powered by Diffusion Optics Technology™**  
**launches in Canada to slow myopia progression**

*Breakthrough Approach First to Use Contrast Management, Supported by Extensive Clinical Studies;  
Proven Highly Effective in Children as Young as Six Years Old*

**Toronto, Ontario, July 1, 2025**—CooperVision today announced the launch of breakthrough MiSight® Spectacle Lenses powered by Diffusion Optics Technology™ for myopia control in Canada.

Diffusion Optics Technology™ uses a unique, patent-protected mechanism to lower contrast signals that can cause myopia progression in children.<sup>1</sup> Beginning July 1st, Canadian Eye Care Professionals will be able to prescribe this proven intervention to help slow the progression of myopia in their young patients.<sup>\*2</sup>

The innovative approach is backed by extensive research, including the pivotal CYPRESS clinical trial conducted across 14 sites in North America<sup>1</sup> and the ongoing CATHAY clinical trial across 5 sites in China.<sup>3</sup> MiSight® Spectacle Lenses slow average myopia progression by up to 75% after 12 months of wear across diverse populations of children.<sup>†1,3</sup>

The rigorous, multi-site four-year CYPRESS clinical trial demonstrated that among children wearing MiSight® Spectacle Lenses, 41% of children showed no meaningful progression in refractive error over 24 months.<sup>†2</sup>

“MiSight® Spectacle Lenses provide another scientifically proven myopia control option alongside our MiSight® 1 day.\* We are enthusiastic about bringing this advancement to Eye Care Professionals in Canada, and about the potential it offers for so many children,” said Enrique Contreras, Country Manager for CooperVision Canada.

“We expect the availability of MiSight® Spectacle Lenses to significantly expand myopia control access<sup>4</sup> for children in Canada, particularly among younger patients for whom spectacles may be a preferred form of treatment. Adding MiSight® Spectacle Lenses to an Eye Care Professional’s toolbox helps to increase access to evidence-based technologies, especially for younger children, which helps drive towards a shared goal of making myopia management a standard of care,” said Andrew Sedgwick, CEO of SightGlass Vision.

MiSight® Spectacle Lenses provide a positive wearing experience with 93% of children saying they love their MiSight® Spectacle Lenses.<sup>1,2</sup> Studies also show that MiSight® Spectacle Lenses provide a clinically equivalent visual experience to standard single vision lenses.<sup>5-7</sup>

For more information, visit [CooperVision.ca](https://CooperVision.ca) and [SightGlassVision.com](https://SightGlassVision.com).

---

\* USA Indication: MiSight® 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with  $\leq 0.75$  diopters of astigmatism. The lens is to be discarded after each removal. **Canadian Indications for Use:** MiSight (omafilcon A) Soft Contact Lenses for Myopia Control may reduce the rate of myopia progression in children (6-18) and correct ametropia. Reduction of myopia progression was observed in children with wearing time of 12 hours (8-16 hours) per day, 6.4 days (5-7) per week in a clinical study. Permanent myopia control after lens treatment is discontinued is not supported by clinical studies. MiSight (omafilcon A) Soft Contact Lenses for Myopia Control are indicated for single-use daily disposable wear. When prescribed for daily disposable wear, the lens is to be discarded after each removal.

± Reduction in progression of spherical equivalent refraction and axial length from baseline over 24 months was 47% and 24% on average, respectively ( $p < 0.0041$ ).

‡ Based on a North American patient population aged 6–10 years (least-squared means) and a Chinese patient population aged 6–13 years (unadjusted means). Significant progression is defined as  $>0.25$  D change from baseline.

† No clinically meaningful change in refractive error means that there was less than a 0.25D increase in myopia from baseline as measured by cycloplegic autorefraction. ( $p < 0.0001$ ).

| Proportion agreeing to “I love my DOT glasses” at the 30-day visit.

## References

1 Rappon et al. Control of myopia using diffusion optics spectacle lenses: 12-month results of a randomized controlled, efficacy and safety study (CYPRESS). Br J Ophthalmol. 2023 Nov; 107(11): 1709:1715.

2 SGV data on file 2021. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 24-month results (n = 256, 14 North American sites).

3 Laughton D., et al. Control of myopia using diffusion optics spectacle lenses in a Chinese population: 12-month results. 2025 ARVO poster presentation. 24-month, randomized and controlled clinical trial across 5 Chinese hospital sites, evaluating DOT spectacle lenses (n=128) versus control standard single vision spectacle lenses (n=58) in myopic children aged 6–13.

4 Rappon et al. Two-year effectiveness of a novel myopia management spectacle lens in full-time wearers. Invest. Ophthalmol. Vis. Sci. 2022;63(7):408.

5 SGV data on file 2022. Control of Myopia Using Peripheral Diffusion Lenses: Efficacy and Safety Study, 3-Year Report (n = 256, 14 North American sites).

6 Laughton D et al. Safety and efficacy of a novel spectacle lens for myopia control over three years. AAOptom conference 2022 presentation.

7 Wolffsohn JS, Hill JS, Laughton D, Hunt C, Young G. Visual Impact of Diffusion Optics Technology Lenses for Myopia Control. AAOptom conference poster presentation 2023.

# # #

### **About CooperVision**

CooperVision, a division of CooperCompanies (Nasdaq: COO), is one of the world's leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges, such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas, and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit [www.coopervision.com](http://www.coopervision.com).

### **About CooperCompanies**

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on improving lives one person at a time. The Company operates through two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, improving the vision of millions of people every day. CooperSurgical is a leading fertility and women's health company dedicated to assisting women, babies and families at the healthcare moments that matter most. Headquartered in San Ramon, Calif., CooperCompanies has a

workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit [www.coopercos.com](http://www.coopercos.com).

### **About SightGlass Vision**

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light scattering elements designed to mimic more natural contrast on the retina—a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

### **Forward-Looking Statements**

This press release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995 including, among others, statements regarding a product launch and features and technologies that may impact demand for new products. Forward-looking statements necessarily depend on assumptions, data or methods that may be incorrect or imprecise and are subject to risks and uncertainties. Among the factors that could cause actual results and future actions to differ materially from those described in forward-looking statements are risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to research and development, regulatory requirements, clinical studies, sales, marketing, and distribution plans and capabilities; potential product performance and quality issues; intellectual property risks; competition; adverse changes in the global or regional general business; and other factors described in CooperCompanies' Securities and Exchange Commission filings, including the "Business", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections in Cooper's Annual Report on Form 10-K for the fiscal year ended October 31, 2023, as such Risk Factors may be updated in annual and quarterly filings. CooperCompanies cautions investors that forward-looking statements reflect the company's analysis only on their stated date. CooperCompanies disclaims any intent to update them except as required by law.

### **Media Contacts**

CooperVision Canada

Mary Doyle

Blend PR for CooperVision Canada

[mary@blendpr.com](mailto:mary@blendpr.com) or (416) 907-0977

SightGlass Vision

Mike McDougall, APR, Fellow PRSA, FAAO

McDougall Communications for SightGlass Vision

+1-585-545-1815 or [mike@mcdougallpr.com](mailto:mike@mcdougallpr.com)